Gordon Carl L's Form 4 filing
Kinnate Biopharma Inc. (KNTE) · filed Feb 15, 2022
- Accession no.
- 0000947871-22-000255
- Filed
- Feb 15, 2022
- Trade date
- Feb 11-15, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions. Open-market purchases total $1.99M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gordon Carl LCIK 0001282930 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 11, 2022 | Common Stock | PPurchaseAcquired | +156,000 | $10.22 | +$1,594,320 | 3,469,330 | Indirect | |
| Feb 14, 2022 | Common Stock | PPurchaseAcquired | +20,700 | $9.98 | +$206,586 | 3,490,030 | Indirect | |
| Feb 14, 2022 | Common Stock | PPurchaseAcquired | +10,000 | $9.89 | +$98,900 | 3,500,030 | Indirect | |
| Feb 15, 2022 | Common Stock | PPurchaseAcquired | +9,000 | $9.96 | +$89,640 | 3,509,030 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.